Literature DB >> 20624114

Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Mingke Yu1, Michael Vajdy.   

Abstract

IMPORTANCE OF THE FIELD: There are currently over thirty million people infected with HIV and there are no vaccines available to prevent HIV infections or disease. The genitourinary, rectal and oral mucosa are the mucosal HIV transmission routes. An effective vaccine that can induce both systemic and local mucosal immunity is generally accepted as a major means of protection against mucosal HIV transmission and AIDS. WHAT THE READER WILL GAIN: Structure and cells that comprise the oral, vaginal and rectal mucosa pertaining to HIV transmission and vaccination strategies through each mucosal route to prevent mucosal and systemic infection will be discussed. AREAS COVERED IN THIS REVIEW: Covering publications from 1980s through 2010, mucosal transmission of HIV and current and previous approaches to vaccinations are discussed. TAKE HOME MESSAGE: Although oral transmission of HIV is far less common than vaginal and rectal transmissions, infections through this route do occur through oral sex as well as vertically from mother to child. Mucosal vaccination strategies against oral and other mucosal HIV transmissions are under intensive research but the lack of consensus on immune correlates of protection and lack of safe and effective mucosal adjuvants and delivery systems hamper progress towards a licensed vaccine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624114      PMCID: PMC2904634          DOI: 10.1517/14712598.2010.496776

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  139 in total

1.  Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM).

Authors:  M A Thapar; E L Parr; J J Bozzola; M B Parr
Journal:  Vaccine       Date:  1991-02       Impact factor: 3.641

2.  Langerhans' cells and lymphocyte subsets in the female genital tract.

Authors:  J N Edwards; H B Morris
Journal:  Br J Obstet Gynaecol       Date:  1985-09

3.  HIV transmission by oral sex.

Authors:  W Rozenbaum; S Gharakhanian; B Cardon; E Duval; J P Coulaud
Journal:  Lancet       Date:  1988-06-18       Impact factor: 79.321

4.  Children born to women with HIV-1 infection: natural history and risk of transmission. European Collaborative Study.

Authors: 
Journal:  Lancet       Date:  1991-02-02       Impact factor: 79.321

5.  HLA-DR-expressing Langerhans'-like cells in vaginal and cervical epithelium.

Authors:  S Bjercke; H Scott; L R Braathen; E Thorsby
Journal:  Acta Obstet Gynecol Scand       Date:  1983       Impact factor: 3.636

6.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.

Authors:  Rosemary Stevens; Kristina E Howard; Sushila Nordone; MaryJo Burkhard; Gregg A Dean
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

Authors:  Shainn-Wei Wang; Frederic M N Bertley; Pamela A Kozlowski; Lara Herrmann; Kelledy Manson; Gail Mazzara; Mike Piatak; R Paul Johnson; Angela Carville; Keith Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2004-08       Impact factor: 2.205

9.  Immunohistochemical localization of immunoglobulins A, G and M in the mouse female genital tract.

Authors:  M B Parr; E L Parr
Journal:  J Reprod Fertil       Date:  1985-07

10.  Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.

Authors:  V Jirathitikal; A S Bourinbaiar
Journal:  Acta Virol       Date:  2004       Impact factor: 1.162

View more
  15 in total

1.  A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

Review 2.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 3.  Mucosal transmission of human immunodeficiency virus.

Authors:  Denis M Tebit; Nicaise Ndembi; Aaron Weinberg; Miguel E Quiñones-Mateu
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

4.  Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac₂₅₁ infection of macaques.

Authors:  Namal P M Liyanage; Shari N Gordon; Melvin N Doster; Poonam Pegu; Monica Vaccari; Nebiyu Shukur; Luca Schifanella; Cynthia A Pise-Masison; Danuta Lipinska; Kamil Grubczak; Marcin Moniuszko; Genoveffa Franchini
Journal:  Virology       Date:  2014-01-21       Impact factor: 3.616

5.  Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.

Authors:  Shailbala Singh; Guojun Yang; Siddappa N Byrareddy; Michael A Barry; K Jagannadha Sastry
Journal:  Vaccine       Date:  2014-11-02       Impact factor: 3.641

6.  Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.

Authors:  Samir K Lakhashe; Vijayakumar Velu; Gaia Sciaranghella; Nagadenahalli B Siddappa; Janet M Dipasquale; Girish Hemashettar; John K Yoon; Robert A Rasmussen; Feng Yang; Sandra J Lee; David C Montefiori; Francis J Novembre; François Villinger; Rama Rao Amara; Maria Kahn; Shiu-Lok Hu; Sufen Li; Zhongxia Li; Fred R Frankel; Marjorie Robert-Guroff; Welkin E Johnson; Judy Lieberman; Ruth M Ruprecht
Journal:  Vaccine       Date:  2011-07-14       Impact factor: 3.641

7.  A chloroplast-derived C4V3 polypeptide from the human immunodeficiency virus (HIV) is orally immunogenic in mice.

Authors:  Néstor Rubio-Infante; Dania O Govea-Alonso; Ángel G Alpuche-Solís; Ana Lilia García-Hernández; Ruth E Soria-Guerra; L M Teresita Paz-Maldonado; Damaris Ilhuicatzi-Alvarado; Javier T Varona-Santos; Leticia Verdín-Terán; Schuyler S Korban; Leticia Moreno-Fierros; Sergio Rosales-Mendoza
Journal:  Plant Mol Biol       Date:  2012-01-07       Impact factor: 4.076

Review 8.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

9.  Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport.

Authors:  Renuka Ramanathan; Jaehyung Park; Sean M Hughes; William R Lykins; Hunter R Bennett; Florian Hladik; Kim A Woodrow
Journal:  Am J Reprod Immunol       Date:  2015-06-27       Impact factor: 3.777

Review 10.  Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.

Authors:  Tomasz Osmałek; Anna Froelich; Barbara Jadach; Adam Tatarek; Piotr Gadziński; Aleksandra Falana; Kinga Gralińska; Michał Ekert; Vinam Puri; Joanna Wrotyńska-Barczyńska; Bozena Michniak-Kohn
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.